EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Risk stratification of prostate cancer with MRI and prostate-specific antigen density-based tool for personalized decision making

Ishwariya Rajendran, Kang-Lung Lee, Liness Thavaraja, Tristan Barrett

British Journal of Radiology · 23.01.2024 · 97 (1153) · 113-119

DOI: 10.1093/bjr/tqad027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Radiology, online erschienen am 12.12.2023. Verfasst von Ishwariya Rajendran und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Addenbrooke's Hospital and University of Cambridge, Cambridge CB2 0QQ, United Kingdom. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

MRI is now established for initial prostate cancer diagnosis; however, there is no standardized pathway to avoid unnecessary biopsy in low-risk patients. Our study aimed to test previously proposed MRI-focussed and risk-adapted biopsy decision models on a real-world dataset.

Methods

Single-centre retrospective study performed on 2055 biopsy naïve patients undergoing MRI. Diagnostic pathways included “biopsy all”, “MRI-focussed” and two risk-based MRI-directed pathways. Risk thresholds were based on prostate-specific antigen (PSA) density as low (<0.10 ng mL−2), intermediate (0.10-0.15 ng mL−2), high (0.15-0.20 ng mL−2), or very high-risk (>0.20 ng mL−2). The outcome measures included rates of biopsy avoidance, detection of clinically significant prostate cancer (csPCa), missed csPCa, and overdiagnosis of insignificant prostate cancer (iPCa).

Results

Overall cancer rate was 39.9% (819/2055), with csPCa (Grade-Group ≥2) detection of 30.3% (623/2055). In men with a negative MRI (Prostate Imaging-Reporting and Data System, PI-RADS 1-2), the risk of cancer was 1.2%, 2.6%, 9.0%, and 12.9% in the low, intermediate, high, and very high groups, respectively; for PI-RADS score 3 lesions, the rates were 10.5%, 14.3%, 25.0%, and 33.3%, respectively. MRI-guided pathway and risk-based pathway with a low threshold missed only 1.6% csPCa with a biopsy-avoidance rate of 54.4%, and the risk-based pathway with a higher threshold avoided 62.9% (1292/2055) of biopsies with 2.9% (61/2055) missed csPCa detection. Decision curve analysis found that the “risk-based low threshold” pathway has the highest net benefit for probability thresholds between 3.6% and 13.9%.

Conclusion

Combined MRI and PSA-density risk-based pathways can be a helpful decision-making tool enabling high csPCa detection rates with the benefit of biopsy avoidance and reduced iPCa detection. Advances in knowledge This real-world dataset from a large UK-based cohort confirms that combining MRI scoring with PSA density for risk stratification enables safe biopsy avoidance and limits the over-diagnosis of insignificant cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsHumansMaleDecision MakingMagnetic Resonance ImagingProstate-Specific AntigenRetrospective StudiesRisk Assessment

Stichwörter der Autor:innen

MRIprostate cancerrisk assessment

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Radiology, Addenbrooke's Hospital and University of Cambridge, Cambridge CB2 0QQ, United Kingdom.
  • Department of Radiology, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
  • School of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan.
  • School of Medicine, Addenbrooke's Hospital, Cambridge CB2 0SP, United Kingdom.

Zitieren

APA

Rajendran, I., Lee, K. L., Thavaraja, L., & Barrett, T. (2024). Risk stratification of prostate cancer with MRI and prostate-specific antigen density-based tool for personalized decision making. British Journal of Radiology, 97(1153), 113-119. https://doi.org/10.1093/bjr/tqad027

Vancouver

Rajendran I, Lee KL, Thavaraja L, Barrett T. Risk stratification of prostate cancer with MRI and prostate-specific antigen density-based tool for personalized decision making. British Journal of Radiology. 2024;97(1153):113-119. doi:10.1093/bjr/tqad027

BibTeX
@article{Rajendran2024,
  author = {Rajendran, Ishwariya and Lee, Kang-Lung and Thavaraja, Liness and Barrett, Tristan},
  title = {Risk stratification of prostate cancer with MRI and prostate-specific antigen density-based tool for personalized decision making},
  journal = {British Journal of Radiology},
  year = {2024},
  volume = {97},
  number = {1153},
  pages = {113--119},
  doi = {10.1093/bjr/tqad027}
}
Kostenlos starten →